I started Exo Advantage because every clinician practicing regenerative medicine should have access to the same high-quality, safe, and affordable protocols that are used by the nation's blood banks and the Red Cross.
An increasing body of literature demonstrates the benefit of high-dose platelet-rich plasma (PRP) for joint preservation in patients suffering from osteoarthritis. Recently, both the AARP and AAOS have advocated for the use of PRP as the first therapy for moderate knee osteoarthritis because it is minimally invasive and effective.
Regenerative medicine procedures are not covered by insurance leaving clinicians in the unenviable position of not being able to offer the same care regardless of a patient's ability to pay. It is not unusual for disadvantaged populations to be unable to afford basic introductory regenerative medicine procedures such as PRP. Many leading regenerative medicine physicians reached out to me to see if I could provide a solution to this problem.
Exo Advantage has addressed this problem head-on. We have developed a one-platform system that combines higher dose biologics, pre-conditioning samples, and exosomes from various autologous tissues that clinicians typically use, to provide an affordable solution for clinicians and patients.
Please reach out to me if you would like to learn more.
Laura McGillicuddy
President, CEO
Exo Advantage LLC
Andrew McGillicuddy
Andrew McGillicuddy is a pioneer in the field of autologous regenerative medicine with over 25 years of experience. He holds numerous patents and patent applications. He has been involved in several successful businesses and product launches.
Andrew McGillicuddy is the first named inventor of the Cervos line of products including the Key PRP, Lipo Pro, and Marrow Cellutions BMA systems, and was one of the earliest employees of Harvest Technologies. He saved his best work for last and is committed to providing unparalleled capabilities at affordable prices.
Our Mission
To offer a superior product that consistently delivers 10 billion platelets per procedure.
To significantly expand the capabilities available such as proteins from plasma(exosomes) and photobiomodulation without increasing cost.
To offer a simple common platform and the ability to process other tissues such as adipose and bone marrow.
To dramatically reduce the cost of providing regenerative medicine services while also introducing transparency to our pricing, so clinics know they are getting a fair price.
New protocols such as photobiomodulation and exosomes are starting to demonstrate a positive and accretive adjunctive benefit to PRP. Other tissues such as bone marrow aspirate and adipose aspirate are also increasingly becoming adopted in regenerative medicine. Common protocols and supplies to work with each tissue improve workflows leading to more reproducible processing results.
We can save you THOUSANDS of dollars per year and you can help your patients by providing a superior biologic. All our products are 510(k) cleared or are registered class 1 devices.
Laura and Andrew McGillicuddy started this company to disrupt the regenerative medicine industry, to end ridiculous prices, and to help patients receive the best care. Please reach out to us to learn more. Thank you for your support!